Communiqués KDventures AB OTC Markets

Actions

KDEVF

SE0002190926

Equipement, fournitures et distribution médicale

Temps réel OTC Markets Autres places de cotation			Varia. 5j.	Varia. 1 janv.
- ^USD	-.--%		-.--%	-

03/08	Umecrine Cognition inclut le dernier patient de son étude	FW
09/07	PharmNovo, société en portefeuille de KD Ventures, lève 39 millions de couronnes	FW

Communiqués

03/08	KDventures' : portfolio company Umecrine Cognition enrolls last patient in ongoing Phase 1b/2a study	PU
03/08	KDventures’ portfolio company Umecrine Cognition enrolls last patient in ongoing Phase 1b/2a study	AQ
09/07	KDventures' : portfolio company PharmNovo secures capital ahead of phase 2 study; holding written down	PU
09/07	KDventures’ portfolio company PharmNovo secures capital ahead of phase 2 study; holding written down	AQ
30/06	Change of number of shares and votes in KDventures AB	AQ
25/06	KDventures' : portfolio company AnaCardio's clinical study of drug candidate AC01 published in The Lancet	PU
25/06	KDventures’ portfolio company AnaCardio’s clinical study of drug candidate AC01 published in The Lancet	AQ
23/06	KDventures’ portfolio company Umecrine Cognition completes interim sample size analysis in ongoing clinical study of golexanolone	AQ
18/06	KDventures AB has carried out a directed issue of a total of 99,516,667 new B shares and raises approximately SEK 23.9 million	AQ
17/06	KDventures AB explores the conditions for carrying out a directed issue	AQ
08/06	KDventures participates in portfolio company Umecrine Cognitions’ share issue and writes down book value	AQ
27/05	KDventures' portfolio company Umecrine Cognition presents new patient data identifying severe fatigue as the most burdensome symptom in PBC	AQ
13/05	KDventures’ portfolio company Umecrine Cognition to present new data highlighting the need for central fatigue and cognitive symptom therapies in PBC	AQ
12/05	KDventures’ Annual General Meeting 2026	AQ
30/04	Interim Report - January-March 2026	AQ
09/04	KDventures’ portfolio company SVF Vaccines partners with Touchlight to accelerate SVF-001 toward clinical development	AQ
07/04	KDventures : Notice of Annual General Meeting in KDventures AB (publ)	PU
20/03	KDventures Annual Report 2025 published	AQ
20/03	KDventures : Annual Report 2025	PU
11/03	KDventures’ portfolio company AnaCardio extends IP protection for AC01 until the 2040s with new US patent approval	AQ
03/03	KDventures announces that Organon has discontinued the development of the previous portfolio company Forendos’ drug candidate for PCOS	GL
27/02	Change of number of shares and votes in KDventures AB	GL
24/02	KDventures’s portfolio company SVF Vaccines announces that the intended merger with Novakand will not be carried out following negative decision from Nasdaq	GL
13/02	Year-end Report - January-December 2025	GL
12/02	KDventures AB (publ) carries out a directed issue of shares to guarantors in connection with the completed rights issue	GL